[Ciclesonide in the treatment of patients with bronchial asthma].
Inhaled glucocorticosteroids are the first choice drugs in the treating of patients with chronic bronchial asthma. Despite the fact that they are considered safe, in some percentage of patients they may cause local and even systemic side effects. Most of those side effects result from low lung / body deposition index of many glucocorticosterois and action of active metabolites of the drugs already in the oral cavity and throat. Ciclesonide is a new steroid characterized by clinical efficacy comparable to that of fluticasone and a lower risk of side effects. Ciclesonide is a prodrug, which is converted into an active metabolite by lung esterases only in the peripheral airways. Due to the use of a novel aerosol propellant--hydrofluoroalkane, available ciclesonide preparations are characterized by a high lung deposition. It is also characterized by low absorption to the systemic circulation. The article presents an current knowledge on pharmacokinetics, clinical efficacy and safety of ciclesonide in patients with bronchial asthma.